How Much Does Farxiga Cost in Vermont in 2026?

Retail Pricing for Farxiga Across Vermont Pharmacies

The manufacturer list price set by AstraZeneca for Farxiga 10 mg (30 tablets) is $620 per month, and Vermont retail pharmacies reflect this figure closely in their cash-pay pricing for 2026. Price variation between pharmacies in Burlington, Montpelier, Rutland, and smaller towns remains minimal because dapagliflozin has no approved generic competitor as of this writing.

Without insurance or a discount card, patients filling at CVS, Walgreens, Rite Aid, or independent Vermont pharmacies should expect to pay within $10 of that $620 benchmark. The SGLT2 inhibitor class as a whole carries premium pricing. Empagliflozin (Jardiance) sits in the same range, so switching within class does not typically reduce cost. Patients who find the cash price prohibitive have several pathways to reduce their burden, detailed in the sections below.

One data point worth noting: AstraZeneca reported $4.3 billion in U.S. Farxiga revenue for 2024, reflecting broad utilization that has not yet translated into generic competition or meaningful price reductions at the pharmacy counter 1.

Vermont Medicaid Coverage for Dapagliflozin

Vermont Medicaid does cover Farxiga, but a prior authorization (PA) requirement applies. The PA process typically requires documentation that the patient has tried and failed, or has a contraindication to, metformin as first-line therapy for type 2 diabetes. For heart failure and chronic kidney disease indications, the PA criteria differ and may require documentation of ejection fraction or eGFR values.

The Vermont Department of Health Access (DVHA) Preferred Drug List places SGLT2 inhibitors in a category requiring step therapy. Prescribers must submit the PA form through the state's pharmacy benefit manager. Approval turnaround in Vermont averages 24 to 72 hours for standard requests.

For the heart failure indication specifically, clinical evidence from the DAPA-HF trial (N=4,744) demonstrated a 26% relative risk reduction in the composite of worsening heart failure or cardiovascular death with dapagliflozin versus placebo (HR 0.74 to 95% CI 0.65-0.85, P<0.001) [2]. This trial data typically strengthens PA approval for patients with HFrEF. The American College of Cardiology and American Heart Association 2022 Heart Failure Guidelines now recommend SGLT2 inhibitors as a Class I therapy for heart failure with reduced ejection fraction [3].

Vermont Medicaid members pay $0 to $3 in copays for preferred drugs once PA is approved, making this the most cost-effective route for eligible patients.

Commercial Insurance Coverage in Vermont

Most commercial health plans sold on Vermont Health Connect (the state's ACA exchange) and employer-sponsored plans through Blue Cross Blue Shield of Vermont, MVP Health Care, and Cigna place Farxiga on Tier 3 (preferred brand) formularies. Tier 3 copays in Vermont typically range from $35 to $75 per month, though high-deductible plans may require patients to pay full price until meeting their deductible.

A 2023 analysis published in Diabetes Care found that SGLT2 inhibitor utilization increased 38% among commercially insured patients when copays fell below $50, suggesting that formulary tier placement directly affects whether patients fill their prescriptions 4.

Patients should verify their specific plan's formulary before filling. Key questions to ask the insurer:

• Is Farxiga on the formulary for my specific indication (diabetes vs. heart failure vs. CKD)?
• Does prior authorization or step therapy apply?
• What is my copay after deductible?
• Does the AstraZeneca savings card apply on top of my insurance benefit?

Some Vermont employers with self-funded plans have carved out SGLT2 inhibitors as preferred based on the cardiovascular and renal outcomes data. Dr. Silvio Inzucchi, professor of medicine at Yale School of Medicine, stated in the ADA Standards of Care commentary: "SGLT2 inhibitors have moved from glucose-lowering agents to cardio-renal protective therapies, and formulary committees should reflect that evolution" 5.

Compounded Dapagliflozin in Vermont: Legality and Access

Compounded dapagliflozin is legal in Vermont through licensed 503A compounding pharmacies. These pharmacies operate under patient-specific prescriptions and must comply with both Vermont Board of Pharmacy regulations and FDA guidance on compounding.

The cost advantage is significant. Compounded dapagliflozin from 503A pharmacies may cost substantially less than brand Farxiga, though pricing varies by pharmacy. However, patients and prescribers should understand the tradeoffs:

Compounded products do not undergo FDA bioequivalence testing. They lack the quality control infrastructure of manufactured tablets. The FDA has issued warning letters to compounding pharmacies for potency and sterility violations [6]. For an oral tablet like dapagliflozin, sterility is less concerning than potency consistency.

Vermont permits out-of-state 503A pharmacies to ship compounded medications into the state provided the pharmacy holds a Vermont non-resident pharmacy license. This expands patient options beyond the handful of in-state compounders.

Patients considering compounded dapagliflozin should confirm with their prescriber that the pharmacy is licensed, that potency testing is performed on each batch, and that the dose matches the 10 mg daily regimen studied in clinical trials. The DAPA-CKD trial used manufactured dapagliflozin 10 mg and showed a 39% reduction in the composite kidney endpoint (HR 0.61, P<0.001, N=4,304), so dosing precision matters for replicating outcomes [7].

AstraZeneca Savings Card and Discount Programs

AstraZeneca offers the Farxiga Savings Card for commercially insured patients. Eligible patients may pay as little as $0 per 30-day fill, with a maximum annual benefit that typically covers 12 fills. The card does not apply to government insurance (Medicare, Medicaid, Tricare, VA).

Eligibility criteria for the savings card:

• Patient must have commercial or private insurance
• Patient must not be enrolled in any federal or state healthcare program
• Prescription must be for an FDA-approved indication

Vermont patients can enroll online or receive activation through their prescriber's office. The card works at all Vermont retail pharmacies and most mail-order pharmacies.

For uninsured patients, AstraZeneca's patient assistance program (AZ&Me) provides Farxiga at no cost to qualifying individuals. Income limits typically fall at 400% of the federal poverty level. A single individual in Vermont earning under approximately $60,240 annually (2026 FPL guidelines) may qualify 8.

Additional discount pathways include GoodRx and RxAssist coupons, which can reduce cash-pay pricing by 10-20% at select Vermont pharmacies, though these rarely bring the price below $500 per month.

Telehealth Prescribing of Farxiga in Vermont

Vermont permits telehealth prescribing of Farxiga without geographic restriction within the state. The Vermont Board of Medical Practice allows prescribers to establish a patient-provider relationship via synchronous audio-video visits, and dapagliflozin is not a controlled substance, so no in-person visit requirement applies.

This means Vermont residents in rural areas (the Northeast Kingdom, for example) can access an endocrinologist, cardiologist, or primary care provider via telehealth and receive a Farxiga prescription sent to their local pharmacy or a mail-order pharmacy.

Telehealth platforms operating in Vermont must use prescribers licensed in the state. The prescription itself can be transmitted electronically to any Vermont pharmacy. For patients pursuing the compounded route, the telehealth prescriber can send the prescription to a licensed 503A pharmacy.

The Endocrine Society Clinical Practice Guideline on type 2 diabetes management notes that SGLT2 inhibitors should be considered early in therapy for patients with established cardiovascular disease or high cardiovascular risk, independent of A1C [9]. Vermont telehealth providers can initiate this therapy after reviewing labs and medical history remotely.

Comparing Cost-Reduction Strategies for Vermont Patients

Each pathway carries different savings potential and different tradeoffs. Here is how they compare for a Vermont patient paying $620/month cash:

Vermont Medicaid (if eligible): Copay of $0-$3/month after PA approval. Best option for income-qualifying patients.

Commercial insurance + AstraZeneca card: Out-of-pocket may reach $0/month for eligible patients. Requires commercial coverage and an FDA-approved indication.

Compounded dapagliflozin (503A): Potentially lower cost per month, but no FDA bioequivalence data and variable quality depending on the pharmacy.

GoodRx/RxAssist coupons: Reduces cash price by 10-20%, still leaves patients paying $500+/month. Least effective option for substantial savings.

AZ&Me patient assistance: Free drug for qualifying uninsured patients under 400% FPL. Requires annual re-enrollment and income documentation.

The CREDENCE trial and DAPA-CKD results have prompted several Vermont insurers to relax prior authorization criteria for patients with CKD stage 3-4, recognizing that SGLT2 inhibitors reduce progression to dialysis [10]. Patients with kidney disease should highlight this data when navigating insurance approvals.

When Generic Dapagliflozin May Reach Vermont

AstraZeneca's composition-of-matter patent for dapagliflozin is expected to expire in 2025-2026, though patent litigation and pediatric exclusivity extensions could delay generic entry. As of May 2026, no FDA-approved generic dapagliflozin is available in the United States.

When generic entry occurs, Vermont patients can expect pricing to drop 70-90% within 12-18 months of the first generic approval, based on historical patterns with other branded diabetes medications. The Congressional Budget Office has estimated that generic SGLT2 inhibitors could save the U.S. healthcare system $3-5 billion annually 11.

Vermont's generic substitution law (18 V.S.A. § 4605) requires pharmacists to dispense the generic equivalent unless the prescriber writes "brand medically necessary" or the patient requests brand. Once a generic dapagliflozin receives FDA approval, Vermont pharmacies will automatically substitute unless otherwise directed.

Clinical Value Supporting the Investment

The cost of Farxiga must be weighed against its clinical benefits across three FDA-approved indications. In DAPA-HF, the number needed to treat (NNT) to prevent one primary composite event over 18.2 months was 21 2. In DAPA-CKD, the NNT was 19 over 2.4 years 7.

A cost-effectiveness analysis published in the Journal of the American College of Cardiology found dapagliflozin cost-effective at a willingness-to-pay threshold of $50,000 per quality-adjusted life year (QALY) for heart failure patients 12. For Vermont patients with heart failure or CKD, the drug's cost is offset by reduced hospitalizations and slower disease progression.

The FDA label for Farxiga 1 notes that dapagliflozin reduced hospitalization for heart failure by 30% in DAPA-HF, a finding that Vermont cardiologists cite when supporting prior authorization requests.